Quick Answer
PMV Pharmaceuticals, Inc. reported Diluted EPS of $1.48 per share (loss) for fiscal year 2025.
PMV Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.48 | -29.8% |
| 2024 | -$1.14 | +20.8% |
| 2023 | -$1.44 | +10.6% |
| 2022 | -$1.61 | -25.8% |
| 2021 | -$1.28 | +46.7% |
| 2020 | -$2.40 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.40 | -8.1% | +2.4% |
| June 30, 2025 | -$0.41 | -1950.0% | -20.6% |
| March 31, 2025 | -$0.34 | -13.3% | +8.1% |
| September 30, 2024 | -$0.37 | -8.8% | -1750.0% |
| June 30, 2024 | -$0.02 | +94.7% | +93.3% |
| March 31, 2024 | -$0.30 | +28.6% | +11.8% |
| September 30, 2023 | -$0.34 | +15.0% | +10.5% |
| June 30, 2023 | -$0.38 | +0.0% | +9.5% |
- PMV Pharmaceuticals, Inc. showed a decrease of -29.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, PMV Pharmaceuticals, Inc.’s diluted eps has grown by 38.3% (from $2.40 per share (loss) to $1.48 per share (loss)).
- The most recent figure is from PMV Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: